For Pfizer and Moderna, the boosters could be more profitable than the original doses because they won#39;t come with the research and development costs the companies incurred to get the vaccines on the market in the first place.from Moneycontrol Business News https://ift.tt/2ZtnExf
No comments:
Post a Comment